The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Yair Lotan

Department of Urology

University of Texas Southwestern Medical Center

Dallas

TX 75390

USA

[email]@utsouthwestern.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 2004 - 2012

References

  1. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system. Lotan, Y., Buendia Jiménez, I., Lenoir-Wijnkoop, I., Daudon, M., Molinier, L., Tack, I., Nuijten, M.J. BJU Int. (2012) [Pubmed]
  2. Words of wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. Lotan, Y. Eur. Urol. (2010) [Pubmed]
  3. The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons. Lotan, Y., Bolenz, C., Gupta, A., Hotze, T., Ho, R., Cadeddu, J.A., Roehrborn, C.G. BJU Int. (2010) [Pubmed]
  4. Economics of robotics in urology. Lotan, Y. Curr. Opin. Urol (2010) [Pubmed]
  5. Role of biomarkers to predict outcomes and response to therapy. Lotan, Y. Urol. Oncol. (2010) [Pubmed]
  6. Economics and cost of care of stone disease. Lotan, Y. Advances. Chronic. Kidney. Disease (2009) [Pubmed]
  7. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. Lotan, Y., Elias, K., Svatek, R.S., Bagrodia, A., Nuss, G., Moran, B., Sagalowsky, A.I. J. Urol. (2009) [Pubmed]
  8. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Lotan, Y., Kamat, A.M., Porter, M.P., Robinson, V.L., Shore, N., Jewett, M., Schelhammer, P.F., deVere White, R., Quale, D., Lee, C.T. Cancer (2009) [Pubmed]
  9. Words of wisdom. Re: Evaluating the learning curve for robot- assisted laparoscopic radical cystectomy. Lotan, Y. Eur. Urol. (2009) [Pubmed]
  10. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. Lotan, Y., Bensalah, K., Ruddell, T., Shariat, S.F., Sagalowsky, A.I., Ashfaq, R. J. Urol. (2008) [Pubmed]
  11. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. Lotan, Y., Shariat, S.F. BJU Int. (2008) [Pubmed]
  12. Screening for bladder cancer: a perspective. Lotan, Y., Svatek, R.S., Malats, N. World. J. Urol (2008) [Pubmed]
  13. Prevention of bladder cancer recurrence by retinoic acid-ketoconazole: a promising strategy?. Lotan, Y., Lotan, R. Cancer Biol. Ther. (2008) [Pubmed]
  14. Are urologists fairly reimbursed for complex procedures: failure of 22 modifier?. Lotan, Y., Bagrodia, A., Roehrborn, C.G., Scott, J. Urology (2008) [Pubmed]
  15. Despite PSA screening and the control by radical prostatectomy, patients treatment fails and have a PSA recurrence. Lotan, Y. Eur. Urol. (2007) [Pubmed]
  16. Economics of stone management. Lotan, Y., Pearle, M.S. Urol. Clin. North Am. (2007) [Pubmed]
  17. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. Lotan, Y., Cadeddu, J.A., Lee, J.J., Roehrborn, C.G., Lippman, S.M. J. Clin. Oncol. (2005) [Pubmed]
  18. A cost comparison of nephron-sparing surgical techniques for renal tumour. Lotan, Y., Cadeddu, J.A. BJU Int. (2005) [Pubmed]
  19. International comparison of cost effectiveness of medical management strategies for nephrolithiasis. Lotan, Y., Cadeddu, J.A., Pearle, M.S. Urol. Res. (2005) [Pubmed]
  20. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. Lotan, Y., Gupta, A., Shariat, S.F., Palapattu, G.S., Vazina, A., Karakiewicz, P.I., Bastian, P.J., Rogers, C.G., Amiel, G., Perotte, P., Schoenberg, M.P., Lerner, S.P., Sagalowsky, A.I. J. Clin. Oncol. (2005) [Pubmed]
  21. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. Lotan, Y., Shariat, S.F., Khoddami, S.M., Saboorian, H., Koeneman, K.S., Cadeddu, J.A., Sagalowsky, A.I., McConnell, J.D., Roehrborn, C.G. J. Urol. (2004) [Pubmed]
  22. The new economics of radical prostatectomy: cost comparison of open, laparoscopic and robot assisted techniques. Lotan, Y., Cadeddu, J.A., Gettman, M.T. J. Urol. (2004) [Pubmed]
  23. The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology. Lotan, Y., Cadeddu, J.A., Roehrborn, C.G., Stage, K.H. J. Urol. (2004) [Pubmed]
 
WikiGenes - Universities